- Clinical, management, and outcome data of study cases.
| Variables | n (%) |
|---|---|
| Total number of patients | 13 (100) |
| Demographics | |
| Age (<30 years) | 11 (85.0) |
| Male | 8 (62.0) |
| Female | 5 (38.0) |
| Co-morbidities | 6 (46.0) |
| Source of poisoning | |
| Source-1 | 6 (46.0) |
| Source-2 | 3 (23.0) |
| Random source | 4 (31.0) |
| Clinical presentation | |
| Incubation period | Few hours - 48 hours |
| Dyspghagia | 11 (85.0) |
| Visual symptoms | 9 (69.0) |
| Speech symptoms | 7 (54.0) |
| UL weakness | 9 (69.0) |
| LL weakness | 7 (54.0) |
| Respiratory symptoms | 7 (54.0) |
| GI symptoms | 8 (62.0) |
| Headach | 3 (23.0) |
| Dizziness | 5 (38.0) |
| IVIG | |
| Patients received IVIG | 7 (54.0) |
| Improvement after IVIG | 2 (29.0) |
| Antitoxin | |
| Patients received antitoxin | 13 (100) |
| Improvement after antitoxin | 12 (92.0) |
| Adverse reactions to antitoxin | 0 (0.0) |
| 3,4-DAP | |
| Patients received 3,4-DAP | 12 (92.0) |
| Improvement after 3,4-DAP | 10 (83.0) |
| Adverse reactions to 3,4-DAP | 2 (17.0) |
| Disease severity and outcome | |
| Patients required ICU care | 12 (92.0) |
| Patient required MV | 1 (8.0) |
| Patient required NIV | 1 (8.0) |
| Patient required HFNC | 2 (15.0) |
| Patients discharged home | 11 (85.0) |
| ICU LOS* | 4 (2-9) days |
| Hospital LOS† | 7 (2-19) days |
UL: upper limb, LL: lower limb, GI: gastrointestinal, IVIG: intravenous immunoglobulin, 3,4-DAP: 3,4-diaminopyridine, MV: mechanical ventilation, NIV: non-invasive ventilation, HFNC: high flow nasal cannula, LOS: length of stay